BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 29278831)

  • 1. Using drugs in un/safe spaces: Impact of perceived illegality on an underground supervised injecting facility in the United States.
    Davidson PJ; Lopez AM; Kral AH
    Int J Drug Policy; 2018 Mar; 53():37-44. PubMed ID: 29278831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'It's our safe sanctuary': Experiences of using an unsanctioned overdose prevention site in Toronto, Ontario.
    Foreman-Mackey A; Bayoumi AM; Miskovic M; Kolla G; Strike C
    Int J Drug Policy; 2019 Nov; 73():135-140. PubMed ID: 31654936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perceptions about supervised injection facilities among people who inject drugs in Philadelphia.
    Harris RE; Richardson J; Frasso R; Anderson ED
    Int J Drug Policy; 2018 Feb; 52():56-61. PubMed ID: 29241143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role of safer injection facilities in reducing HIV and hepatitis C infections and overdose mortality in the United States.
    Semaan S; Fleming P; Worrell C; Stolp H; Baack B; Miller M
    Drug Alcohol Depend; 2011 Nov; 118(2-3):100-10. PubMed ID: 21515001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives on supervised injection facilities among service industry employees in New York City: A qualitative exploration.
    Wolfson-Stofko B; Elliott L; Bennett AS; Curtis R; Gwadz M
    Int J Drug Policy; 2018 Dec; 62():67-73. PubMed ID: 30359875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A micro-environmental intervention to reduce the harms associated with drug-related overdose: evidence from the evaluation of Vancouver's safer injection facility.
    Kerr T; Small W; Moore D; Wood E
    Int J Drug Policy; 2007 Jan; 18(1):37-45. PubMed ID: 17689342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The projected costs and benefits of a supervised injection facility in Seattle, WA, USA.
    Hood JE; Behrends CN; Irwin A; Schackman BR; Chan D; Hartfield K; Hess J; Banta-Green C; Whiteside L; Finegood B; Duchin J
    Int J Drug Policy; 2019 May; 67():9-18. PubMed ID: 30802842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Willingness to use a supervised injection facility among young adults who use prescription opioids non-medically: a cross-sectional study.
    Bouvier BA; Elston B; Hadland SE; Green TC; Marshall BD
    Harm Reduct J; 2017 Feb; 14(1):13. PubMed ID: 28219388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia.
    Roxburgh A; Jauncey M; Day C; Bartlett M; Cogger S; Dietze P; Nielsen S; Latimer J; Clark N
    Harm Reduct J; 2021 Feb; 18(1):20. PubMed ID: 33596940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supervised injection facilities in Canada: past, present, and future.
    Kerr T; Mitra S; Kennedy MC; McNeil R
    Harm Reduct J; 2017 May; 14(1):28. PubMed ID: 28521829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The implementation of overdose prevention sites as a novel and nimble response during an illegal drug overdose public health emergency.
    Wallace B; Pagan F; Pauly BB
    Int J Drug Policy; 2019 Apr; 66():64-72. PubMed ID: 30708237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supervised Injection Facilities as Harm Reduction: A Systematic Review.
    Levengood TW; Yoon GH; Davoust MJ; Ogden SN; Marshall BDL; Cahill SR; Bazzi AR
    Am J Prev Med; 2021 Nov; 61(5):738-749. PubMed ID: 34218964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supervised injection services: what has been demonstrated? A systematic literature review.
    Potier C; Laprévote V; Dubois-Arber F; Cottencin O; Rolland B
    Drug Alcohol Depend; 2014 Dec; 145():48-68. PubMed ID: 25456324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York City.
    Behrends CN; Paone D; Nolan ML; Tuazon E; Murphy SM; Kapadia SN; Jeng PJ; Bayoumi AM; Kunins HV; Schackman BR
    J Subst Abuse Treat; 2019 Nov; 106():79-88. PubMed ID: 31540615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of COVID-19 public health measures on attendance and overdose at supervised injecting facilities in Australia.
    Roxburgh A; Livingston M; Dietze P; Nielsen S; Cogger S; Bartlett M; Day C; Latimer J; Jauncey M; Clark N
    Public Health; 2023 Nov; 224():90-97. PubMed ID: 37742585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility.
    Irwin A; Jozaghi E; Weir BW; Allen ST; Lindsay A; Sherman SG
    Harm Reduct J; 2017 May; 14(1):29. PubMed ID: 28532488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opening Canada's first Health Canada-approved supervised consumption sites.
    Patterson T; Bharmal A; Padhi S; Buchner C; Gibson E; Lee V
    Can J Public Health; 2018 Aug; 109(4):581-584. PubMed ID: 30039262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The willingness of people who inject drugs in Boston to use a supervised injection facility.
    León C; Cardoso L; Mackin S; Bock B; Gaeta JM
    Subst Abus; 2018 Jan; 39(1):95-101. PubMed ID: 28799847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supervised Injection Facility Utilization Patterns: A Prospective Cohort Study in Vancouver, Canada.
    Kennedy MC; Klassen DC; Dong H; Milloy MS; Hayashi K; Kerr TH
    Am J Prev Med; 2019 Sep; 57(3):330-337. PubMed ID: 31377091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing risk and presentation of overdose associated with consumption of street drugs at a supervised injection site in Vancouver, Canada.
    Notta D; Black B; Chu T; Joe R; Lysyshyn M
    Drug Alcohol Depend; 2019 Mar; 196():46-50. PubMed ID: 30665151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.